Summary: Neonatal seizures frequently accompany neonatal encephalopathies. Seizures occur in ∼1.8-5/1,000 live births in this country and are caused by virtually any condition that affects neonatal brain function. This review provides a simple classification of seizures and emphasizes that many abnormal intermittent behaviors in this age group are not accompanied by ictal EEG patterns. Additionally, Յ50% of neonatal seizures are not associated with abnormal clinical behavior. This is a common phenomenon, particularly after anticonvulsant treatment in which the clinical seizures are suppressed but electrographic seizures continue unabated. Seizures also may be caused by genetic disorders, several of which are benign, familial, and caused by channelopathies involving potassium channels. The review also discusses the epileptic syndromes seen in neonates, including early myoclonic encephalopathy, Ohtahara syndrome, pyridoxine dependency, and glucose transporter type 1 syndrome.
Seizures are a common manifestation of encephalopathy in newborn infants including the very small premature. They occur in ∼0.15-3.5% of newborns. The National Collaborative Perinatal Project (1) reported an incidence of five per 1,000, whereas in a more recent population-based study in a single county in Kentucky, the risk was 3.5/1,000 (2) . The incidence in infants born between 1992 and 1994 in Harris County, Texas, was 1.8/1,000 live births (3) .
In some studies the incidence was high in very small prematures, decreased in older prematures, and increased again in term infants. In others, including the Texas study, the incidence decreased as birth weight increased. In all these studies, some or all of the infants were identified with seizures solely on the basis of clinical events (in the Kentucky study, for example, only 22% of the infants with presumed seizures had confirmatory ictal EEGs). It is now well known that many seizure-like episodes in neonates are not associated with concomitant electrographic abnormalities. Some may actually be seizures arising from deeper sites, such as the hippocampus, or even the brainstem or cerebellum, and not be recorded by distant scalp electrodes or be limited surface events with restricted fields on the scalp. Many represent abnormal nonepileptic motor phenomena that arise from brainstem centers as a consequence of the reduction of neocortical inhibitory input secondary to a diffuse encephalopathy, so-called "brainstem release phenomena." These nonepileptic events are quite common, for example, in encephalopathic premature infants with massive intraparenchymal hemorrhages and extensive white-matter damage and term infants with hypoxicischemic encephalopathy (HIE). They are probably caused by the removal of the normal cortical inhibitory input as well as by a direct disturbance of brainstem function from increased intracranial pressure, temporal lobe herniation, or subarachnoid blood.
Infants with severe encephalopathies often have subtle seizures (e.g., brief deviation of the eyes, cessation of normal motor activity, apnea, autonomic symptoms, and subtle posturing), which may be missed by trained personal. Additionally a significant number of infants, >50% in several studies, have electrographic seizures only. These seizures would be missed without continuous EEG monitoring. Electrographic-only seizures usually occur in infants with diffuse encephalopathies, those who have received anticonvulsant drugs (AEDs), particularly barbiturates, and in iatrogenically paralyzed infants. It is well known, for example, that infants with clinical status epilepticus often remain in electrographic status after the clinical events are eliminated by parenteral phenobarbital (PB).
Neonatal seizures are usually self-limited and spontaneously disappear in days to a few weeks. Seizures wane when the causative encephalopathy resolves (e.g., HIE, meningitis, and hemorrhage). Many infants, particularly those with static encephalopathies, will experience seizures later in life after a seizure-free period of months to years. Seizures also may continue beyond the neonatal period without a seizure-free interval in some infants (Table 1) .
ETIOLOGY
It is beyond the scope of this review to discuss the cause of neonatal seizures, which includes virtually every encephalopathy of infancy. Table 2 lists some of the most common etiologies.
The diagnostic workup should include metabolic tests, particularly if a structural abnormality is not obvious (Table 3) The first four items in Table 3 should be done expeditiously. One should search for acute reversible causes that, if left untreated, could lead to significant injury (e.g., hypoglycemia, sepsis, acidosis, hypocalcemia, and hyperammonemia). These metabolic perturbations also may be markers of a more serious inborn error of metabolism that, if left untreated, could have serious long-term consequences. A trial of pyridoxine and folinic acid should be considered if seizures persist and no etiology is apparent (4).
Classification of neonatal seizures
Many behavioral events previously called seizures have been shown by long-term monitoring to lack an ictal electrographic signature. Certain clinical events (focal clonic and tonic and some myoclonic movements) are usually accompanied by ictal EEG patterns, whereas others (generalized tonic, oral-buccal, and motor automatisms) are infrequently associated with a cortical discharge. They can be suppressed by gentle restraint or repositioning and precipitated by stimulation. The extent of the involvement, including the amplitude of the muscular contraction and the number of muscles involved, often increases with each stimulation ("recruiting response"), consistent with a brainstem release mechanism. Table 4 presents a clinical classification of neonatal seizures. Seizure types underlined are more likely to be accompanied by ictal EEG abnormalities.
Progressive epileptic syndromes in the first year of life with onset in the neonatal period
Several well-defined syndromes have their onset in the neonatal period. In some individuals, the cause is known, whereas in others, with virtually identical symptoms, none is found.
1. Early (neonatal) myoclonic encephalopathy (EME) is characterized by erratic, fragmentary myoclonic jerks that begin in the first month of life, often in the first week of life. These are followed by partial seizures, massive myoclonus, and infantile spasms and, infrequently, tonic seizures. The EEG shows a characteristic suppressionburst pattern (S-B; bursts of spikes, sharp waves, and slow activity lasting 5-6 s, alternating with 4-to 12-s periods of attenuation). The EEG often evolves into a hypsarhythmic pattern or a markedly abnormal back- ground with multifocal spikes and sharp waves. These infants have an obvious encephalopathy from birth with markedly delayed milestones, symmetric hypotonia, and progressive microcephaly from cerebral atrophy. The etiology is often not found, although some cases are familial and due to an inborn metabolic disorder (e.g., glycine encephalopathy, D-glyceric acidemia, propionic acidemia, methylmalonic acidemia). Infants with similar clinical courses but without the S-B EEG pattern also have been described. Intrauterine seizures (due to cerebral dysgenesis) (5), a pyridoxine-dependent syndrome, and hydranencephaly also have been reported with EME.
Early infantile epileptic encephalopathy with S-B EEG pattern (EIEE; Ohtahara syndrome)
is often confused with early myoclonic encephalopathy. The EEG abnormalities are very similar, and the etiologies may overlap. This disorder is characterized by intractable tonic seizures in the neonatal period or early infancy (often with an ictal EEG pattern similar to that accompanying typical infantile spasms in older infants). Seizures are accompanied by a severe encephalopathy, which progresses to other seizure syndromes including infantile massive spasms (IMSs) with hypsarrhythmia, partial seizures with multifocal spike foci on the EEG, and the Lennox-Gastaut syndrome. In some instances, the seizures may disappear, despite the persistence of the severe encephalopathy.
Many infants with EIEE have cerebral dysgenesis, including major brain malformation. Ohtahara (6) , in one of his earlier articles reporting 14 cases, described cerebral dysgenesis in eight, porencephaly in two, nonspecific atrophy in one; three infants had no obvious pathology. Aicardi syndrome also has been associated with EIEE. Williams (7) described the first case of EIEE with a neurometabolic cause: cytochrome oxidase deficiency (complex IV), diagnosed with a muscle biopsy. Lombroso (8) described several infants with symptoms and EEGs consistent with EME caused by a hypoxic-ischemic encephalopathy. The seizures, however, stopped after several weeks, which is not typical of EME. He found no significant differences in the EEG S-B pattern in these two syndromes but emphasized that tonic seizures were more common in EIEE (and may occur in series or clusters similar to IMS) and myoclonic seizures typified EME. He also recognized a more severe course in EIEE, the rarity of neurometabolic etiologies in EIEE, and the occurrence of cerebral dysgenesis in both. He also pointed out that the S-B pattern may resemble the pattern seen during sleep in some infants with typical IMS, who do not have a hypsarrhythmic EEG pattern during wakefulness. He considered EIEE an early variant of IMS.
Infants with EIEE may rarely have a focal cortical dysplasia with asymmetric tonic seizures and S-B pattern. Some have been helped by resective surgery (9).
We recently saw an infant with EIEE whose magnetic resonance imaging (MRI) showed typical hemimegalencephaly (Figs. 1-3) . The child's seizures were completely eliminated by a hemispherectomy at age 7 months.
Miller et al. (10) described an infant with EIEE and a diffuse neuronal migration disorder with cortical laminar disorganization, microdysgenesis, abnormal hippocampi, and immature neurons in both amygdalae and bilateral enlargement of the dentate and olivary nuclei. The MRI showed only atrophy and a thin corpus callosum. There also was an absence of ␥-aminobutyric acid (GABA) in the cerebrospinal fluid (CSF), and the positron emission tomography (PET) scan showed decreased metabolism in both frontal lobes and left anterior temporal lobe.
Cerebral dysgenesis is a well-recognized cause of infantile and neonatal seizures. It should be kept in mind, however, that cerebral dysgenesis may be caused by a neurometabolic disorder that disturbs early fetal brain development. An MRI that shows a migrational disorder, therefore, should not stop the investigation for another etiology of the infant's seizures. Table 5 lists some of the metabolic disorders that have been associated with cerebral dysgenesis. Some have been reported with EME.
3. Glucose transporter type 1 syndrome (Glu-1 deficiency syndrome; Glut-1 DS) is probably more common than the small number of reported cases would suggest (>40 patients as of July 2000; D. DeVivo, personal correspondence). It is characterized by infantile seizures (complex partial, atypical absences, and generalized myoclonic and tonic-clonic), usually beginning between ages 6 and 12 weeks, progressive postnatal microcephaly, and developmental delay including ataxia (11) (12) (13) (14) (15) (16) (17) . The infants may initially appear normal with rare neonatal seizures, but later in the first year of life, the seizure frequency increases, and the delay in development becomes evident. The encephalopathy is caused by a deficiency of GLUT-1 (positionally mapped to 1p35-p31.3), resulting in decreased transport of glucose at the bloodbrain barrier and across astroglial cell membranes and markedly reduced brain and CSF glucose (CSF/blood ratio of <0.65; CSF glucose usually <40 mg/dl). CSF lactate is usually in the lower range of normal (elevated lactate levels would suggest a mitochondrial disorder). DeVivo's group (11) initially reported two distinct classes of mutations as the molecular basis for the functional defect of glucose transport: hemizygosity of GLUT-1 and nonsense mutation resulting in truncation of the GLUT-1 protein. Subsequent studies have discovered a variety of mutations including large-scale deletions, missense mutations, deletions, insertions, splice-site mutations, as well as nonsense mutations (12) .
GLUT-1 is multifunctional; in addition to transporting galactose, water, and glycopeptides, it also transports dehydroascorbic acid (DHAS), the oxidized form of vita-min C. This latter property formed the basis of an early diagnostic blood test that measured the transport of DHAS into red blood cells (RBCs). In patients with glucose transporter protein syndrome (GTPS), there is a reduced uptake into the RBCs (13) . A recently developed RBC assay uses 14 C-labeled 3-O-methyl-D-glucose uptake and is the diagnostic test of choice (14) .
The encephalopathy is treated with the ketogenic diet, which supplies the necessary energy to the brain in the absence of glucose. Long-term outcome data are not available on the effectiveness of this diet. One of our patients with GTPS had an improvement of his encephalopathy with the diet but continued to receive PB for his seizures. After Klepper et al. (15) reported that barbiturates may inhibit glucose transport mediated by GLUT-1 and could theoretically worsen the encephalopathy of GTPSs, we switched him to carbamazepine (CBZ) with seizure control. It also is advised that caffeine-containing beverages and other methylxanthines, which have a similar effect on the glucose transporter, be avoided by these individuals (15) . De Vivo (personal correspondence) also recommends thioctic (␣-lipoic) acid as a dietary supplement (200-600 mg daily). Thioctic acid in vitro increases the expression of the Glut-1 gene.
Although initially thought to be caused by a spontaneous mutation, the syndrome has recently been reported in several families with what appears to be dominant transmission (17) . The phenotype was quite mild in some of the involved family members, suggesting that many cases may be missed if they are mildly mentally retarded and without seizures. 
Pyridoxine-dependent seizures (PDSs).
The seizures in this autosomal recessive disorder usually have their onset between birth and age 3 months, although occasional cases have been reported with onset at 3 years. Seizures usually appear within 6 h of birth and not uncommonly are recognized in utero. Despite treatment, some children are mentally retarded, and some will develop MRI evidence of a leukodystrophy, particularly in the frontal and occipital areas, and cerebral atrophy (19, 20) . It is a rare disorder with an estimated point prevalence of one per 687,000 (21) .
The EEG abnormalities are relatively nonspecific and consist of focal and multifocal epileptiform discharges, bursts of generalized spike-and-wave activity, photoparoxysmal responses, stimulus-induced myoclonus, and occasionally an S-B pattern in the neonatal period and hypsarrhythmia later in the first year. Mikati et al. (22) described an unusual 1-to 4-Hz ictal pattern in four patients, which they thought was highly suggestive of this disorder. In our experience, this pattern may occur in other neonatal encephalopathies.
The intravenous (i.v.) pyridoxine test (50-100 mg i.v.) is usually positive, with prompt cessation of seizures and disappearance of epileptiform activity over the next few hours. The test should be repeated if the response is equivocal or transient. There are often transient responses to parenteral B 6 in infants who do not have this syndrome. There also are reports of infants and children who have a dramatic response to the injection, with apnea and hypotonia and, occasionally, coma, respiratory arrest, and an isoelectric EEG. (It is speculated that this dramatic effect to B 6 is caused by the sudden increase in brain GABA levels) (23, 24) .
Patients usually require life-long B 6 therapy. Although 50-100 mg daily usually controls the seizures, higher doses may be needed. Very high doses (Յ2,000 mg) have been used but can cause a sensory neuropathy (25) . Pyridoxine also may suppress seizures in children with other epileptic disorders, and some have even recommended it as an adjunct to standard AED therapy (26, 27) . These latter cases appear not to have pyridoxinedependent seizures. The inclusion of such cases in epidemiologic studies may lead to an overestimation of the incidence of this syndrome. If a child has complete seizure control with oral B 6 , all AEDs should be discontinued, and after 6-12 months, a trial of B 6 reduction considered.
The biochemical cause of this syndrome is unknown. An inborn defect in pyridoxine metabolism has not been found. Reduced levels of GABA and increased glutamate have been found in the CSF and the cerebral cortex (28) . The latter may be normalized by pyridoxine (29) .
Plecko et al. (30) reported significant elevations of pipecolic acid concentrations in the plasma and CSF of two patients with B 6 -responsive seizures. They found that the degree of pipecolic acid elevation was inversely correlated with plasma pyridoxal phosphate levels and speculated that there was an enzyme defect in a pyridoxine-dependent step in pipecolic acid degradation, although they did not identify that enzyme. 6. Fifth-day fits. These neonatal seizures of unknown etiology usually begin toward the end of the first week of life. They were first reported by the French as a distinct clinical and EEG syndrome (31, 32) .
These authors estimated that 2-7% of neonatal seizures could be classified as "fifth-day fits." Convulsions were usually partial clonic, often with apnea, and occurred in 90% of infants between days 4 and 6 of life. Status epilepticus was not infrequent and could last several days. Interictal EEG abnormalities were nonspecific, except that 60% showed an unusual pattern with bursts of sharply contoured theta activity, particularly in the central regions ("theta pointu alternant") (31, 32) . This pattern has not been seen by other authors (33) , and in our experience, can occur in a variety of encephalopathies including HIE without seizures. Very few cases of this syndrome have been reported since the early 1980s, and it has been suggested that the seizures may have caused by a transient zinc deficiency or a virus.
7. Genetic neonatal epilepsy syndromes A. Benign familial neonatal convulsions (BFNCs). These are autosomal dominant disorders with ∼85% penetrance. The seizures usually begin by the third day of life and are clonic, tonic, and partial, often with automatisms. Myoclonic seizures are rare. The infants are neurologically normal, and most have a spontaneous remission; ∼10-15% will have subsequent epilepsy, usually generalized motor seizures. A single case of infantile spasms has been reported in a family with BFNC (34). Baxter and Kandler (35) reported an infant whose seizures presumably began in utero. Several families have been reported with familial and nonfamilial neonatal seizures and benign rolandic epilepsy (benign epilepsy with central temporal spikes) (BECTS). Linkage of BECTS has not been demonstrated on chromosomes associated with BFNC (36) .
The gene for this disorder has been localized to two chromosomes in many, but not all, of the families: BFNC is one of three idiopathic epileptic syndromes caused by a single gene mutation. The others are autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE; caused by a mutation of the ␣ 4 subunit of the neuronal nicotinic acetylcholine receptor) and generalized epilepsy with febrile seizures plus (GEFC+; a mutation in a voltage-gated sodium channel SCN1B).
Ronen et al. (37) reported the clinical and electrographic features of a large kindred (69 affected individuals) in Newfoundland, Canada, with BFNC 1. Forty-two percent had seizure onset on days 2-5, and 68% stopped seizing during the first 6 weeks of life. Interictal EEGs were usually normal, whereas ictal recordings showed a pattern that has been described by others and thought to be quite characteristic of BFNC (37, 38) . Sixteen percent of their patients had subsequent epilepsy (median age at onset, 8 years), and half of them continued having seizures into adulthood. They suggested that the seizures had a "subcortical, possibly brainstem origin" because of the initial ictal EEG feature of generalized suppression of the background and the high incidence of ictal tonic, autonomic, and facial symptoms in their population. Initial reports on this syndrome suggested that only the chromosome 20 families had later epilepsy; however, chromosome 8q24 patients also may have seizures later in childhood (39) .
How do these K+ channel mutations lead to epilepsy? KCNQ3 gains its K+ channel function as a heterotetramer with KCNQ2. The two genes act synergistically in the formation of the native M-current, a slowly activating and deactivating K+ conductance that regulates the excitability of neurons. In the inner ear, KCNQ3 forms a heterotetramer with KCNQ4, and its mutation results in autosomal dominant sensorineural deafness. Mutations of KCNQ1 produce the long-QT syndrome with deafness (Lange-Nielsen).
The mutation in KCNQ2 (BFNC 1) truncates the last 300 amino acids and leads to a nonfunctional channel protein. This causes a hyperexcitable neuron through a reduced potassium-dependent repolarization of the neuronal membrane, similar to mutations in KCNQ1 in the long-QT syndrome.
In the Italian family studied by Lerche et al. (40) , a novel mutation within the distal, unconserved C-terminal domain of KCNQ2 caused a 1-bp deletion, 2513delG, in codon 838, predicting substitution of the last seven amino acids and the addition of another 56 amino acids. They expressed the mutation in Xenopus oocytes and caused a reduction of the potassium current to 5% of the wild-type current (impaired repolarization), but voltage sensitivity and kinetics were not significantly changed. A second artificial mutation yielded a stop codon at position 838, and the K+ current increased twofold, indicating that the pathologic amino acid extension produced the phenotype of BFNC and suggested an important role of the distal, unconserved C-terminal domain of this channel.
B. Benign familial infantile convulsions. These syndromes typically begin later in the first year of life, but in some families, neonatal seizures are seen.
Watanabe et al. (41) described a group of infants
with the onset of partial seizures at 3-10 months. Seizures tended to occur in clusters and were characterized by motion arrest, decreased responsiveness, staring or "blank eyes" with simple automatisms and mild convulsive movements. Ictal
EEGs showed focal paroxysmal discharges. Four of their patients had a family history of benign infantile convulsions. The interictal EEG and development were normal. 2. Singh et al. (42) described nine families with a dominantly inherited epileptic disorder associated with febrile seizures. The most common phenotype was febrile seizures plus (FS+; febrile seizures that continued beyond 6 years or were associated with afebrile generalized tonic-clonic seizures; GTCSs). These were usually gone by adolescence but could continue into adulthood. Additionally the phenotypes included typical FSs, as well as other seizure types (absences, myoclonic, or atonic seizures) and myoclonic-astatic epilepsy (MAE). The disorder was linked to chromosome 2q23-31. The mean age at onset of the FS+ was 1.4 years (range, 6 weeks to 4 years), and for MAE, 1.5 years (range, 6 weeks to 4.5 years). All but one child had an onset with fever, and four had an explosive onset with myoclonic, absence, and GTCSs. In five cases, there were atonic head nods. All had falls due to myoclonic seizures, or tonic or atonic seizures. EEGs showed irregular 2.5-to 4-Hz generalized spikeand-wave or polyspike-wave discharges. Two or more phenotypes within the GEFS+ spectrum were observed in each family.
Linkage to chromosomes 19q (43), SCN1B, a Na+-channel ␤ 1 subunit gene, and 2q24-q33 (44) also has been reported. The inheritance in these families is autosomal dominant with 54-89% penetrance in different families.
Escayg et al. (45) describe two mutations in SCN1A in two families with GEFS+2, which probably cause a decrease in the rate of channel inactivation resulting in increased Na+ influx, increased excitability of neurons, and increased seizure susceptibility.
